UAFRS vs As Reported Weekly Highlights - 2019 05 29
This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for DISC.A, INGN and NUVA.Discovery, through its subsidiaries, is a media company that provides content across distribution platforms, including pay-television, free-to-air and broadcast television, and direct-to-consumer subscription products. The company's portfolio of networks includes nonfiction television brands such as Discovery Channel, HGTV, Food Network, TLC, Animal Planet, Science Channel, and MotorTrend . The company's portfolio includes Eurosport, a sports entertainment provider. The company classifies its operations in two segments: U.S. Networks, consisting of domestic television networks and digital content services, and International Networks, consisting of international television networks and digital content services.
Inogen is a medical technology company that primarily develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company's proprietary Inogen One? systems concentrate the air around the patient to provide a single source of supplemental oxygen the company markets its existing portable product offerings, the Inogen One G4 and the Inogen One G3, as single solutions for long-term oxygen therapy. The company's solutions can operate on a 24/7 basis for at least 60 months without a stationary concentrator, with minimal servicing of sieve beds, filters, and accessories.
Nuvasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. The company's principal product offering includes a minimally disruptive surgical platform, Maximum Access Surgery. The platform includes the company's proprietary software-driven nerve detection and avoidance systems, and Intraoperative Monitoring services and support; MaXcess, an integrated split-blade retractor system; and implants and biologics. The company's spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable surgeon access to the spine to perform restorative and fusion procedures.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.